{
  "cohort": "ER+/HER2- MBC, 2L, Site B, by Provider (2024–2025)",
  "insight_type": "Provider Variation at Site B",
  "summary": "Dr. Johnson has a 18% CDK4/6i utilization rate, 17% below Site B average. Targeted intervention could yield $30,000/year.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Dr. Johnson", "value": 18, "gap": -17, "highlight": true },
      { "name": "Dr. Kim", "value": 42, "gap": 7, "highlight": false },
      { "name": "Dr. Garcia", "value": 45, "gap": 10, "highlight": false }
    ],
    "benchmark": 35,
    "nccn_target": 35
  },
  "financial_impact": {
    "annual_opportunity": "$30,000/year",
    "math": "$30,000/year = 8 patients × $3,750 margin per patient"
  },
  "clinical_impact": {
    "description": "Improving Dr. Johnson's utilization increases survival.",
    "quantitative": "+7.4 months PFS"
  },
  "peer_comparison": {
    "description": "Site B average is 35%.",
    "peer_benchmark": 35
  },
  "weighted_score": 74,
  "action_steps": [
    "Schedule 1:1 meeting with Dr. Johnson",
    "Provide CDK4/6i clinical pathway resources",
    "Review Dr. Johnson's patient selection criteria"
  ],
  "suggestions": [
    "Share best practices from Dr. Kim with Dr. Johnson"
  ],
  "drilldowns": []
} 